Acorah Software Products - Accounts Production 15.0.600 false true 31 December 2022 1 January 2022 false 1 January 2023 31 December 2023 31 December 2023 07881789 Professor Mohammad Alavijeh Dr Ghassem Poormand Professor Mohammad Alavijeh iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 07881789 2022-12-31 07881789 2023-12-31 07881789 2023-01-01 2023-12-31 07881789 frs-core:Non-currentFinancialInstruments 2023-12-31 07881789 frs-core:SharePremium 2023-12-31 07881789 frs-core:ShareCapital 2023-12-31 07881789 frs-bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 07881789 frs-bus:FilletedAccounts 2023-01-01 2023-12-31 07881789 frs-bus:SmallEntities 2023-01-01 2023-12-31 07881789 frs-bus:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 07881789 frs-bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 07881789 frs-core:UnlistedNon-exchangeTraded 2023-12-31 07881789 frs-core:UnlistedNon-exchangeTraded 2022-12-31 07881789 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2022-12-31 07881789 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2023-12-31 07881789 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2023-12-31 07881789 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2022-12-31 07881789 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2023-12-31 07881789 frs-bus:Director1 2023-01-01 2023-12-31 07881789 frs-bus:Director2 2023-01-01 2023-12-31 07881789 frs-bus:CompanySecretary1 2023-01-01 2023-12-31 07881789 frs-countries:EnglandWales 2023-01-01 2023-12-31 07881789 2021-12-31 07881789 2022-12-31 07881789 2022-01-01 2022-12-31 07881789 frs-core:Non-currentFinancialInstruments 2022-12-31 07881789 frs-core:SharePremium 2022-12-31 07881789 frs-core:ShareCapital 2022-12-31
Registered number: 07881789
Pharmidex Holdings Ltd
Financial Statements
For The Year Ended 31 December 2023
Contents
Page
Company Information 1
Balance Sheet 2
Notes to the Financial Statements 3
Page 1
Company Information
Directors Professor Mohammad Alavijeh
Dr Ghassem Poormand
Secretary Professor Mohammad Alavijeh
Company Number 07881789
Registered Office 167-169 Great Portland Street
Fifth Floor
London
W1W 5PF
Page 1
Page 2
Balance Sheet
Registered number: 07881789
2023 2022
Notes £ £ £ £
FIXED ASSETS
Investments 4 1,684,863 1,601,663
1,684,863 1,601,663
TOTAL ASSETS LESS CURRENT LIABILITIES 1,684,863 1,601,663
Creditors: Amounts Falling Due After More Than One Year 5 (1,181,702 ) (1,098,502 )
NET ASSETS 503,161 503,161
CAPITAL AND RESERVES
Called up share capital 6 143,777 143,777
Share premium account 359,384 359,384
SHAREHOLDERS' FUNDS 503,161 503,161
For the year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Professor Mohammad Alavijeh
Director
24 September 2024
The notes on page 3 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Pharmidex Holdings Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 07881789 . The registered office is 167-169 Great Portland Street, Fifth Floor, London, W1W 5PF.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Investments
Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
2.3. Borrowings
Borrowings are recorded at fair value, net of transaction costs. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2022: NIL)
- -
4. Investments
Unlisted
£
Cost
As at 1 January 2023 1,601,663
Additions 83,200
As at 31 December 2023 1,684,863
Provision
As at 1 January 2023 -
As at 31 December 2023 -
Net Book Value
As at 31 December 2023 1,684,863
As at 1 January 2023 1,601,663
Unlisted investments comprise shares in group undertaking and participating interests.
5. Creditors: Amounts Falling Due After More Than One Year
2023 2022
£ £
Amounts owed to related parties 1,181,702 1,098,502
6. Share Capital
2023 2022
£ £
Allotted, Called up and fully paid 143,777 143,777
7. Related Party Transactions
Amounts owed to related parties includes borrowings secured by way of a charge over all the company assets. No interest is charged and no repayment dates have been set.
Page 3